Table of contents
- Background
- The case at hand—Sanofi & Regeneron v Amgen (UPC CFI 505/2024)
- Validity
- Infringement
- Implications for bioscience patents and second medical use claims at the UPC
Article summary
Life Sciences analysis: Chris Weekes, Technical Assistant at D Young & Co, considers a recent landmark decision on the infringement of a second medical use patent, highlighting how the Unified Patent Court (UPC) may treat this type of claim.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial